New Protein Expression Kit Enables Serum-free, Stable Cell Line Development under cGMP Guidelines

CARLSBAD, Calif.–Invitrogen, a division of Life Technologies (NASDAQ:LIFE), today announced the launch of the GIBCO® OptiCHO™ Protein Express Kit, a new integrated solution for simple and efficient development of serum-free, stable cell lines for biotherapeutic development. This is the first kit of its kind to provide cells banked under cGMP conditions, enabling biotherapeutics manufacturers to speed regulatory submissions and time to market.

The GIBCO OptiCHO Protein Express Kit enables biotherapeutics manufacturers to develop stable cell lines where proteins of therapeutic interest can be expressed and reproduced. It incorporates all of the reagents, protocols and documentation required to go from gene to stable cell clones expressing the protein of interest within a completely serum-free process. All of the products within the workflow are animal-origin free, which supports biomanufacturers’ ability to enhance the safety of human therapeutics.

The OptiCHO kit is available for research use; however, laboratories interested in pursuing regulatory filings and are in need of a documentation package, can purchase a commercial use license for a one- time fee, with no maintenance costs or royalties required. This is unlike other stable cell line development systems that require expensive research and commercial use licenses, royalties and maintenance fees.

“As the regulatory climate for biotherapeutics continues to tighten, we are providing our customers a competitive advantage with improved product safety controls and cGMP documentation to support the development of therapeutic proteins in stable cell lines,” said Christopher Linthwaite, Vice President of Invitrogen Bioproduction for Life Technologies’ Cell Systems Division. “The OptiCHO Protein Express Kit provides a complete solution for efficient and cost-effective stable cell line development, while providing documentation to support faster regulatory filings and commercialization.”

The OptiCHO Protein Expression Kit can be used as part of a complete workflow for stable cell line development that can be enhanced with use of the Countess™ Automated Cell Counter to simplify the cell counting steps of the protocol. Optimized components within the kit, such as TOPO® TA Cloning® kits enable faster, more efficient creation of vectors and FreeStyle™ MAX Transfection Reagents provide highly efficient, animal-origin-free lipid transfection.

Invitrogen is a leading provider of platform independent, essential life science technologies for disease and drug research, bioproduction and diagnostics. Invitrogen, together with Applied Biosystems ¯ a global leader in providing innovative instrument systems to accelerate academic and clinical research, drug discovery and development, pathogen detection and forensic DNA analysis ¯ is part of Life Technologies Corporation, which markets the life science industry’s most comprehensive portfolio of solutions for molecular and cell biology. Invitrogen and Applied Biosystems products are used in nearly every major laboratory in the world. For more information, please visit: www.invitrogen.com and www.appliedbiosystems.com.

Additional Resources

White Paper: “Considerations for the Development of Stable Cell Lines from Parental Lines”

Article: “Improving Protein Production in CHO Cells” BioPharm International

Product Brochure: OptiCHO Protein Express Kit

Performance Data

About Life Technologies

Life Technologies Corporation (NASDAQ:LIFE) is a global biotechnology tools company dedicated to improving the human condition. Our systems, consumables and services enable researchers to accelerate scientific exploration, driving to discoveries and developments that make life even better. Life Technologies customers do their work across the biological spectrum, working to advance personalized medicine, regenerative science, molecular diagnostics, agricultural and environmental research, and 21st century forensics. Life Technologies had sales of more than $3 billion in 2008, employs approximately 9,500 people, has a presence in more than 100 countries, and possesses a rapidly growing intellectual property estate of approximately 3,600 patents and exclusive licenses. Life Technologies was created by the combination of Invitrogen Corporation and Applied Biosystems Inc. For more information on how we are making a difference please visit our website: www.lifetechnologies.com.

Safe Harbor Statement

This press release includes forward-looking statements about our anticipated results that involve risks and uncertainties. Some of the information contained in this press release, including, but not limited to, statements as to industry trends and Life Technologies’ plans, objectives, expectations and strategy for its business, contains forward-looking statements that are subject to risks and uncertainties that could cause actual results or events to differ materially from those expressed or implied by such forward-looking statements. Any statements that are not statements of historical fact are forward-looking statements. When used, the words “believe,” “plan,” “intend,” “anticipate,” “target,” “estimate,” “expect” and the like, and/or future tense or conditional constructions (“will,” “may,” “could,” “should,” etc.), or similar expressions, identify certain of these forward-looking statements. Important factors which could cause actual results to differ materially from those in the forward-looking statements are detailed in filings made by Life Technologies with the Securities and Exchange Commission. Life Technologies undertakes no obligation to update or revise any such forward-looking statements to reflect subsequent events or circumstances.

Copyright 2009. Life Technologies Corporation. All rights reserved. Invitrogen is a trademark of Life Technologies in the US and/or certain other countries. GIBCO®, OptiCHO™, FreeStyle™ TOPO®, TA Cloning® and Countess™ are trademarks of Invitrogen and Life Technologies Corporation.

Photos/Multimedia Gallery Available: https://www.businesswire.com/cgi-bin/mmg.cgi?eid=5930796&lang=en